Ko G N, Korpi E R, Kirch D G
Psychiatry Service, Bronx Veterans Administration Medical Center, New York 10468.
J Clin Psychopharmacol. 1989 Jun;9(3):186-90.
In a double-blind, placebo-controlled study, 15 drug-free chronic schizophrenic inpatients were treated with a fixed dose of haloperidol for 6 weeks. Haloperidol and its metabolite, reduced haloperidol, were measured in plasma and red blood cells after 2, 4, and 6 weeks of treatment. Behavioral change was rated using the Brief Psychiatric Rating Scale (BPRS). Not only the raw concentrations, but also blood compartment sums and ratios of these four drug measurements were tested for their strength of association with behavioral improvement. Positive associations with some BPRS subscales at some time points emerged; however, no significant correlations were found to extend across all time points measured. There was a trend in this cohort for negative symptom improvement to be associated with the ratio of haloperidol to reduced haloperidol in red blood cells. The ratio of haloperidol to reduced haloperidol in plasma was always greater than that in the red blood cells for all patients, reflecting an accumulation of the metabolite in red blood cells.
在一项双盲、安慰剂对照研究中，15名未服用药物的慢性精神分裂症住院患者接受了固定剂量的氟哌啶醇治疗，为期6周。在治疗2周、4周和6周后，测定血浆和红细胞中的氟哌啶醇及其代谢产物去氢氟哌啶醇。使用简明精神病评定量表（BPRS）对行为变化进行评分。不仅对这四种药物测量的原始浓度，而且对血室总和及比率，都测试了它们与行为改善的关联强度。在某些时间点出现了与一些BPRS分量表的正相关；然而，在所有测量的时间点上均未发现显著相关性。在该队列中存在一种趋势，即阴性症状的改善与红细胞中氟哌啶醇与去氢氟哌啶醇的比率相关。对于所有患者，血浆中氟哌啶醇与去氢氟哌啶醇的比率始终高于红细胞中的比率，这反映了代谢产物在红细胞中的积累。
